Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS

PharmacoEconomics

Volumn 19, Issue 5, 2001, Pages 535-550

  Lee, Todd ^a   Sullivan, Sean D ^a   Veenstra, David L ^a   Ramsey, Scott D ^a,b   Steger, Patrick J K ^c   Malinverni, Raffaele ^d   Pleil, Andreas M ^e   Williamson, Todd ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Pharmacia and Upjohn   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST UTILITY ANALYSIS; CYTOMEGALOVIRUS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; RELAPSE; RETINITIS; SIDE EFFECT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; ECONOMICS, PHARMACEUTICAL; FOSCARNET; GANCICLOVIR; HUMANS; MODELS, ECONOMIC; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; SWITZERLAND; TREATMENT FAILURE;

EID: 0034998770     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119050-00008     Document Type: Article

References (0)